michigan semaglutide gi obstruction class action gastric intestinal louisiana semaglutide gastrointestinal obstruction lawsuit semaglutide obstruction lawyer in louisiana Louisiana Ozempic Lawsuit Lawyer glp-1 gastric intestinal obstruction class

What Id genuinely like to see, and what the field needs, is a properly conducted Phase III randomised controlled trial in fibromyalgia patients, ideally with a sub-group of people with hypermobility and EDS, using low to moderate doses and with muscle mass, GI function, and bone health as pre-specified safety endpoints

The earliest it could hit the market would be late 2026, though it's more likely to drop in 2027

These medications are only available to people with a body mass index (BMI) of 27 or over with at least one weight-related health condition or those with a BMI of 30 or over

As these medications help individuals achieve significant weight loss and improve glycemic control, the focus is naturally shifting towards optimizing the quality of this weight loss

Hormonal, genetic, metabolic